Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.

Vibeke StrandAlejandro BalsaJamal Al-SalehLeonor Barile-FabrisTakahiko HoriuchiTsutomu TakeuchiSadiq LulaCharles HawesBlerina KolaLisa Marshall

Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2018)

Based on reviewed reports, biologic/biosimilar immunogenicity differs among agents, with the highest rates observed with infliximab and adalimumab. As ADAb formation in biologic-/biosimilar-treated patients may increase the risk of lost response, the immunogenicity of these agents is an important (albeit not the only) consideration in the treatment decision-making process.

Keyphrases

rheumatoid arthritis
end stage renal disease
decision making
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
oxidative stress
ulcerative colitis
emergency department
patient reported outcomes
juvenile idiopathic arthritis
smoking cessation